Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Myeloid Leukemia
  • Age: Between 18 - 60 Years
  • Gender: Male or Female

Inclusion Criteria
Confirmed diagnosis of de novo AML
Adequate hepatic function within 48 hours prior to induction chemotherapy
Adequate renal functions within 48 hours prior to induction chemotherapy
Exclusion Criteria
Acute promyelocytic leukemia (APL)
Known clinically active central nervous system (CNS) leukemia
Severe liver disease - Active infections
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known infection with human immunodeficiency virus (HIV)
Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176